255 related articles for article (PubMed ID: 34454995)
1. Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma.
Ricke J; Schinner R; Seidensticker M; Gasbarrini A; van Delden OM; Amthauer H; Peynircioglu B; Bargellini I; Iezzi R; De Toni EN; Malfertheiner P; Pech M; Sangro B
J Hepatol; 2021 Dec; 75(6):1387-1396. PubMed ID: 34454995
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
3. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.
Ricke J; Klümpen HJ; Amthauer H; Bargellini I; Bartenstein P; de Toni EN; Gasbarrini A; Pech M; Peck-Radosavljevic M; Popovič P; Rosmorduc O; Schott E; Seidensticker M; Verslype C; Sangro B; Malfertheiner P
J Hepatol; 2019 Dec; 71(6):1164-1174. PubMed ID: 31421157
[TBL] [Abstract][Full Text] [Related]
4. Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.
Hiraoka A; Kumada T; Kudo M; Hirooka M; Koizumi Y; Hiasa Y; Tajiri K; Toyoda H; Tada T; Ochi H; Joko K; Shimada N; Deguchi A; Ishikawa T; Imai M; Tsuji K; Michitaka K;
Dig Dis; 2017; 35(6):602-610. PubMed ID: 29040999
[TBL] [Abstract][Full Text] [Related]
5. Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.
Walton M; Wade R; Claxton L; Sharif-Hurst S; Harden M; Patel J; Rowe I; Hodgson R; Eastwood A
Health Technol Assess; 2020 Sep; 24(48):1-264. PubMed ID: 33001024
[TBL] [Abstract][Full Text] [Related]
6. NEMESIS: Noninferiority, Individual-Patient Metaanalysis of Selective Internal Radiation Therapy with
Venerito M; Pech M; Canbay A; Donghia R; Guerra V; Chatellier G; Pereira H; Gandhi M; Malfertheiner P; Chow PKH; Vilgrain V; Ricke J; Leandro G
J Nucl Med; 2020 Dec; 61(12):1736-1742. PubMed ID: 32358087
[TBL] [Abstract][Full Text] [Related]
7. Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma.
Ogasawara S; Chiba T; Ooka Y; Suzuki E; Kanogawa N; Saito T; Motoyama T; Tawada A; Kanai F; Yokosuka O
Invest New Drugs; 2015 Dec; 33(6):1257-62. PubMed ID: 26462681
[TBL] [Abstract][Full Text] [Related]
8. Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Michitaka K; Deguchi A; Ishikawa T; Imai M; Ochi H; Joko K; Shimada N; Tajiri K; Hirooka M; Koizumi Y; Hiasa Y; Tanaka J
J Gastroenterol Hepatol; 2019 Jun; 34(6):1066-1073. PubMed ID: 30549320
[TBL] [Abstract][Full Text] [Related]
9. Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC.
Ricke J; Bulla K; Kolligs F; Peck-Radosavljevic M; Reimer P; Sangro B; Schott E; Schütte K; Verslype C; Walecki J; Malfertheiner P;
Liver Int; 2015 Feb; 35(2):620-6. PubMed ID: 24930619
[TBL] [Abstract][Full Text] [Related]
10. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use.
Kuo YH; Wang JH; Hung CH; Rau KM; Wu IP; Chen CH; Kee KM; Hu TH; Lu SN
J Gastroenterol Hepatol; 2017 Dec; 32(12):1975-1981. PubMed ID: 28295594
[TBL] [Abstract][Full Text] [Related]
11. Role of Baseline Albumin-Bilirubin Grade on Predict Overall Survival Among Sorafenib-Treated Patients With Hepatocellular Carcinoma in Vietnam.
Nguyen TTH; Nguyen VH; Nguyen VH; Nguyen TL; Le VQ
Cancer Control; 2019; 26(1):1073274819865269. PubMed ID: 31364390
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.
Kolamunnage-Dona R; Berhane S; Potts H; Williams EH; Tanner J; Janowitz T; Hoare M; Johnson P
J Hepatol; 2021 Oct; 75(4):879-887. PubMed ID: 34052255
[TBL] [Abstract][Full Text] [Related]
13. Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment.
Hu K; Yuan J; Tang B; Zhang F; Lu S; Chen R; Zhang L; Ren Z; Yin X
Ann Transl Med; 2021 Feb; 9(3):237. PubMed ID: 33708864
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of platelet-to-lymphocyte and neutrophil-to-lymphocyte ratio in HCC treated with sorafenib and radioembolization.
Öcal O; Kimm MA; Hoang TPT; Pech M; Öcal E; Ben Khaled N; Sangro B; Ricke J; Seidensticker M; Wildgruber M
JHEP Rep; 2024 Apr; 6(4):100995. PubMed ID: 38440069
[TBL] [Abstract][Full Text] [Related]
15. Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2.
Kudo M; Galle PR; Brandi G; Kang YK; Yen CJ; Finn RS; Llovet JM; Assenat E; Merle P; Chan SL; Palmer DH; Ikeda M; Yamashita T; Vogel A; Huang YH; Abada PB; Yoshikawa R; Shinozaki K; Wang C; Widau RC; Zhu AX
JHEP Rep; 2021 Apr; 3(2):100215. PubMed ID: 33392490
[TBL] [Abstract][Full Text] [Related]
16. Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study.
Palmer DH; Hawkins NS; Vilgrain V; Pereira H; Chatellier G; Ross PJ
Future Oncol; 2020 Jan; 16(1):4315-4325. PubMed ID: 31797680
[No Abstract] [Full Text] [Related]
17. ALBI and P-ALBI grade in Child-Pugh A patients treated with drug eluting embolic chemoembolization for hepatocellular carcinoma.
Carling U; Røsok B; Line PD; Dorenberg EJ
Acta Radiol; 2019 Jun; 60(6):702-709. PubMed ID: 30205701
[TBL] [Abstract][Full Text] [Related]
18. Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial.
Öcal O; Rössler D; Gasbarrini A; Berg T; Klümpen HJ; Bargellini I; Peynircioglu B; van Delden O; Schulz C; Schütte K; Iezzi R; Pech M; Malfertheiner P; Sangro B; Ricke J; Seidensticker M
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2487-2496. PubMed ID: 34541612
[TBL] [Abstract][Full Text] [Related]
19. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.
Kudo M; Ueshima K; Ikeda M; Torimura T; Tanabe N; Aikata H; Izumi N; Yamasaki T; Nojiri S; Hino K; Tsumura H; Kuzuya T; Isoda N; Yasui K; Aino H; Ido A; Kawabe N; Nakao K; Wada Y; Yokosuka O; Yoshimura K; Okusaka T; Furuse J; Kokudo N; Okita K; Johnson PJ; Arai Y;
Gut; 2020 Aug; 69(8):1492-1501. PubMed ID: 31801872
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial.
Yoon SM; Ryoo BY; Lee SJ; Kim JH; Shin JH; An JH; Lee HC; Lim YS
JAMA Oncol; 2018 May; 4(5):661-669. PubMed ID: 29543938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
